WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H328701
CAS#: 75821-71-5 (Lonazolac Calcium)
Description: Lonazolac Calcium, also known as Floxan and Irritren, is a nonsteroidal anti-inflammatory drug (NSAID) used to treat inflammation and pain.
Hodoodo Cat#: H328701
Name: Lonazolac Calcium
CAS#: 75821-71-5 (Lonazolac Calcium)
Chemical Formula: C34H24CaCl2N4O4
Exact Mass: 0.00
Molecular Weight: 663.568
Elemental Analysis: C, 61.54; H, 3.65; Ca, 6.04; Cl, 10.68; N, 8.44; O, 9.64
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 75821-71-5 (Lonazolac Calcium) 53808-88-1 (Lonazolac),
Synonym: Lonazolac Calcium; Floxan; Irritren;
IUPAC/Chemical Name: calcium 2-(3-(4-chlorophenyl)-1-phenyl-1H-pyrazol-4-yl)acetate
InChi Key: CAQGVXNKMLYRMF-UHFFFAOYSA-L
InChi Code: InChI=1S/2C17H13ClN2O2.Ca/c2*18-14-8-6-12(7-9-14)17-13(10-16(21)22)11-20(19-17)15-4-2-1-3-5-15;/h2*1-9,11H,10H2,(H,21,22);/q;;+2/p-2
SMILES Code: O=C([O-])CC1=CN(C2=CC=CC=C2)N=C1C3=CC=C(Cl)C=C3.O=C([O-])CC4=CN(C5=CC=CC=C5)N=C4C6=CC=C(Cl)C=C6.[Ca+2]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info: Related CAS# 75821-71-5 (Lonazolac Calcium) 53808-88-1 (Lonazolac)
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 663.57 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Rubio Lotvin B, Ruíz Moreno JA, González Ansorena R, Ibarrola E, Uranga G, Benítez E. [Calcium lonazolac and blood loss in users of intrauterine devices. Preliminary report]. Ginecol Obstet Mex. 1986 Aug;54:221-4. Spanish. PubMed PMID: 3781294.
2: Deneke J, Luckow V, Guserle R, Pässler HH. Transsynovial kinetics of lonazolac and its hydroxy metabolite in synovitis patients. Int J Clin Pharmacol Ther. 1998 Aug;36(8):418-24. PubMed PMID: 9726694.
3: Raulf M, König W. Effects of the nonsteroidal anti-inflammatory compounds Lonazolac Ca, indomethacin and NDGA on inflammatory mediator generation and release from various cells. Immunopharmacology. 1990 Mar-Apr;19(2):103-11. PubMed PMID: 1693604.
4: Kullich W, Fromme K, Klein G. [Gastroduodenal tolerance and clinical effectiveness of therapy with lonazolac-calcium in rheumatic diseases]. Wien Med Wochenschr. 1996;146(17):459-64. German. PubMed PMID: 9045528.
5: Pavelka K. [Lonazolac-Calcium. A new non-steroidal antirheumatic agent for the treatment of progressive polyarthritis. A long-term open controlled trial]. Fysiatr Revmatol Vestn. 1984 Apr;62(2):80-7. Czech. PubMed PMID: 6378745.
6: Riedel R. [Lonazolac-Ca = Calcium [3-(p-chlorophenyl)-1-phenylpyrazole-4[ -acetate 1 Pharmacological properties of a new antiinflammatory/antirheumatic drug (author's transl)]. Arzneimittelforschung. 1981;31(4):655-65. German. PubMed PMID: 6972772.
7: Dijs H, Verheyen G, Guastavino V, De Vroey T, Deckers K, Driessens M. Clinical experience with lonazolac-calcium in the treatment of osteo-arthritis. Acta Belg Med Phys. 1990 Oct-Dec;13(4):213-5. PubMed PMID: 2097865.
8: Janssen M, Van Leeuwen MH, Albrecht H, Dijkmans BA. A double-blind parallel group comparative study of lonazolac-calcium and diclofenac in patients with rheumatoid arthritis. Clin Rheumatol. 1988 Dec;7(4):545-7. PubMed PMID: 3246140.
9: Rainer G, Krüger U, Klemm K. [Synthesis and physico-chemical properties of lonazolac-Ca, a new antiphlogistic/antirheumatic agent]. Arzneimittelforschung. 1981;31(4):649-55. German. PubMed PMID: 6972771.
10: Georgescu C, Dumitrescu C, Dănău M, Spandonidis S, Costache G. Therapy with irritren in rheumatic degenerative diseases. Med Interne. 1986 Apr-Jun;24(2):147-51. PubMed PMID: 3487823.
